1
|
Di Fruscia P, Carbone A, Bottegoni G, Berti F, Giacomina F, Ponzano S, Pagliuca C, Fiasella A, Pizzirani D, Ortega JA, Nuzzi A, Tarozzo G, Mengatto L, Giampà R, Penna I, Russo D, Romeo E, Summa M, Bertorelli R, Armirotti A, Bertozzi SM, Reggiani A, Bandiera T, Bertozzi F. Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent N-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral Administration. J Med Chem 2021; 64:13327-13355. [PMID: 34469137 PMCID: PMC8474119 DOI: 10.1021/acs.jmedchem.1c00575] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Indexed: 12/30/2022]
Abstract
Inhibition of intracellular N-acylethanolamine-hydrolyzing acid amidase (NAAA) activity is a promising approach to manage the inflammatory response under disabling conditions. In fact, NAAA inhibition preserves endogenous palmitoylethanolamide (PEA) from degradation, thus increasing and prolonging its anti-inflammatory and analgesic efficacy at the inflamed site. In the present work, we report the identification of a potent, systemically available, novel class of NAAA inhibitors, featuring a pyrazole azabicyclo[3.2.1]octane structural core. After an initial screening campaign, a careful structure-activity relationship study led to the discovery of endo-ethoxymethyl-pyrazinyloxy-8-azabicyclo[3.2.1]octane-pyrazole sulfonamide 50 (ARN19689), which was found to inhibit human NAAA in the low nanomolar range (IC50 = 0.042 μM) with a non-covalent mechanism of action. In light of its favorable biochemical, in vitro and in vivo drug-like profile, sulfonamide 50 could be regarded as a promising pharmacological tool to be further investigated in the field of inflammatory conditions.
Collapse
Affiliation(s)
- Paolo Di Fruscia
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Anna Carbone
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
- Department
of Biological, Chemical and Pharmaceutical Sciences and Technologies
(STEBICEF), University of Palermo, 90123Palermo, Italy
| | - Giovanni Bottegoni
- Computational
and Chemical Biology, Istituto Italiano
di Tecnologia (IIT), 16163Genova, Italy
| | - Francesco Berti
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Francesca Giacomina
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Stefano Ponzano
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Chiara Pagliuca
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Annalisa Fiasella
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Daniela Pizzirani
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Jose Antonio Ortega
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Andrea Nuzzi
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Glauco Tarozzo
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Luisa Mengatto
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Roberta Giampà
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Ilaria Penna
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Debora Russo
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Elisa Romeo
- D3-Validation, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Maria Summa
- Analytical
Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Rosalia Bertorelli
- Analytical
Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Andrea Armirotti
- Analytical
Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Sine Mandrup Bertozzi
- Analytical
Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Angelo Reggiani
- D3-Validation, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Tiziano Bandiera
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| | - Fabio Bertozzi
- D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163Genova, Italy
| |
Collapse
|
2
|
Manaithiya A, Alam O, Sharma V, Javed Naim M, Mittal S, Khan IA. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus. Bioorg Chem 2021; 113:104998. [PMID: 34048996 DOI: 10.1016/j.bioorg.2021.104998] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 05/05/2021] [Accepted: 05/17/2021] [Indexed: 02/07/2023]
Abstract
Diabetes mellitus type 2 (T2D) is a group of genetically heterogeneous metabolic disorders whose frequency has gradually risen worldwide. Diabetes mellitus Type 2 (T2D) has started to achieve a pandemic level, and it is estimated that within the next decade, cases of diabetes might get double due to increase in aging population. Diabetes is rightly called the 'silent killer' because it has emerged to be one of the major causes, leading to renal failure, loss of vision; besides cardiac arrest in India. Thus, a clinical requirement for the oral drug molecules monitoring glucose homeostasis appears to be unmet. GPR119 agonist, a family of G-protein coupled receptors, usually noticed in β-cells of pancreatic as well as intestinal L cells, drew considerable interest for type 2 diabetes mellitus (T2D). GPR119 monitors physiological mechanisms that enhance homeostasis of glucose, such as glucose-like peptide-1, gastrointestinal incretin hormone levels, pancreatic beta cell-dependent insulin secretion and glucose-dependent insulinotropic peptide (GIP). In this manuscript, we have reviewed the work done in the last five years (2015-2020) which gives an approach to design, synthesize, evaluate and study the structural activity relationship of novel GPR119 agonist-based lead compounds. Our article would help the researchers and guide their endeavours in the direction of strategy and development of innovative, effective GPR119 agonist-based compounds for the management of diabetes mellitus type 2.
Collapse
Affiliation(s)
- Ajay Manaithiya
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India
| | - Ozair Alam
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India.
| | - Vrinda Sharma
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India
| | - Mohd Javed Naim
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India
| | - Shruti Mittal
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India
| | - Imran A Khan
- Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi-110062, India
| |
Collapse
|
3
|
Maertens G, Saavedra OM, Vece V, Reyes MAV, Hocine S, Öney E, Goument B, Mirguet O, Le Tiran A, Gloanec P, Hanessian S. Design and synthesis of bridged piperidine and piperazine isosteres. Bioorg Med Chem Lett 2018; 28:2627-2630. [PMID: 29937060 DOI: 10.1016/j.bmcl.2018.06.038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Accepted: 06/17/2018] [Indexed: 01/11/2023]
Abstract
We have developed versatile methods toward the synthesis of a variety of piperidine/piperazine bridged isosteres of pridopidine. The compounds were assessed against the D2 receptor in agonist and antagonist modes and against the D4 receptor in agonist mode. hERG Binding and the ADME profiles were studied.
Collapse
Affiliation(s)
- Gaëtan Maertens
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Oscar M Saavedra
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Vito Vece
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Miguel A Vilchis Reyes
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Sofiane Hocine
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Esat Öney
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Bertrand Goument
- Institut de Recherches Servier, 11 rue des Moulineaux, 92150 Suresnes, France
| | - Olivier Mirguet
- Institut de Recherches Servier, 11 rue des Moulineaux, 92150 Suresnes, France
| | - Arnaud Le Tiran
- Institut de Recherches Servier, 11 rue des Moulineaux, 92150 Suresnes, France
| | - Philippe Gloanec
- Institut de Recherches Servier, 11 rue des Moulineaux, 92150 Suresnes, France
| | - Stephen Hanessian
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada.
| |
Collapse
|
4
|
Neelamkavil SF, Stamford AW, Kowalski T, Biswas D, Boyle C, Chackalamannil S, Xia Y, Jayne C, Neustadt B, Hao J, Liu H, Dai X, Baker H, Hawes B, O’Neill K, Tang H, Greenlee WJ. Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes. ACS Med Chem Lett 2018; 9:457-461. [PMID: 29795759 PMCID: PMC5949837 DOI: 10.1021/acsmedchemlett.8b00073] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Accepted: 04/10/2018] [Indexed: 11/30/2022] Open
Abstract
The ever-growing prevalence of type 2 diabetes in the world has necessitated an urgent need for multiple orally effective agents that can regulate glucose homeostasis with a concurrent reduction in body weight. G-Protein coupled receptor 119 (GPR119) is a GPCR target at which agonists have demonstrated glucose-dependent insulin secretion and shows beneficial effects on glycemic control. Herein, we describe our efforts leading to the identification of a potent, oral GPR-119 agonist, MK-8282, which shows improved glucose tolerance in multiple animal models and has excellent off-target profile. The key design elements in the compounds involved a combination of a fluoro-pyrimidine and a conformationally constrained bridged piperidine to impart good potency and efficacy.
Collapse
Affiliation(s)
- Santhosh F. Neelamkavil
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Andrew W. Stamford
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Timothy Kowalski
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Dipshikha Biswas
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Craig Boyle
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Samuel Chackalamannil
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Yan Xia
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Charles Jayne
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Bernard Neustadt
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jinsong Hao
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Hong Liu
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xing Dai
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Hana Baker
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Brian Hawes
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Kim O’Neill
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Huadong Tang
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - William J. Greenlee
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
5
|
Tyurenkov IN, Ozerov AA, Kurkin DV, Logvinova EO, Bakulin DA, Volotova EV, Borodin DD. Structure and biological activity of endogenous and synthetic agonists of GPR119. RUSSIAN CHEMICAL REVIEWS 2018. [DOI: 10.1070/rcr4737] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A G-protein-coupled receptor, GPR119, is a promising pharmacological target for a new class of hypoglycaemic drugs with an original mechanism of action, namely, increase in the glucose-dependent incretin and insulin secretion. In 2005, the first ligands were found and in the subsequent years, a large number of GPR119 agonists were synthesized in laboratories in various countries; the safest and most promising agonists have entered phase I and II clinical trials as agents for the treatment of type 2 diabetes mellitus and obesity. The review describes the major endogenous GPR119 agonists and the main trends in the design and modification of synthetic structures for increasing the hypoglycaemic activity. The data on synthetic agonists are arranged according to the type of the central core of the molecules.
The bibliography includes 104 references.
Collapse
|
6
|
Saturated Heterocycles with Applications in Medicinal Chemistry. ADVANCES IN HETEROCYCLIC CHEMISTRY 2017. [DOI: 10.1016/bs.aihch.2016.03.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
7
|
Matsuoka RT, Boros EE, Brown AD, Bullock KM, Canoy WL, Carpenter AJ, Cobb JD, Condon SE, Deschamps NM, Elitzin VI, Erickson G, Fang JM, Igo DH, Joshi BK, Kaldor IW, Mitchell MB, Peckham GE, Reynolds DW, Salmon MC, Sharp MJ, Tabet EA, Toczko JF, Wu LM, Zhou XMM. Development of Large-Scale Routes to Potent GPR119 Receptor Agonists. Org Process Res Dev 2016. [DOI: 10.1021/acs.oprd.6b00157] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Richard T. Matsuoka
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Eric E. Boros
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Andrew D. Brown
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Kae M. Bullock
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Will L. Canoy
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Andrew J. Carpenter
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Jeremy D. Cobb
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Shannon E. Condon
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Nicole M. Deschamps
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Vassil I. Elitzin
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Greg Erickson
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Jing M. Fang
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - David H. Igo
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Biren K. Joshi
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Istvan W. Kaldor
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Mark B. Mitchell
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Gregory E. Peckham
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Daniel W. Reynolds
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Matthew C. Salmon
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Matthew J. Sharp
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Elie A. Tabet
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Jennifer F. Toczko
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Lianming Michael Wu
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Xiao-ming M. Zhou
- API Chemistry Department, ‡Analytical Science & Development Department, #Medicinal Chemistry Department, and §Particle Sciences and Engineering Department, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| |
Collapse
|
8
|
|